Side effects and perceptions following Sinopharm COVID-19 vaccination.
Side effects and perceptions following Sinopharm COVID-19 vaccination.
复制标题
DOI：
10.1016/j.ijid.2021.08.013
复制
发表时间：
2021-10
期刊：
影响因子：
--
通讯作者：
Adrees AO
中科院分区：
文献类型：
--
作者：
Saeed BQ;Al-Shahrabi R;Alhaj SS;Alkokhardi ZM;Adrees AO
疫苗是根除COVID-19的最佳干预措施之一。本研究旨在为国药集团COVID-19疫苗副作用提供证据。于2021年1月至4月期间进行了一项横断面调查研究，以收集有关COVID-19疫苗在阿拉伯联合酋长国个人中的影响的数据。报告了人口统计数据、疫苗接种和不愿接种COVID-19疫苗的人的反应。首次接种疫苗后的副作用正常注射部位疼痛、疲劳和头痛在≤ 49岁的受试者中比>49岁的受试者更常见，而接种部位疼痛、疲劳、嗜睡、头痛和压痛是两组中第二次接种后最常见的副作用。两种剂量的所有副作用在年龄≤49岁的受试者中更普遍。两种剂量的副作用在女性中比男性更常见。不愿接种COVID-19疫苗的最常见原因是疫苗无效。第一剂和第二剂疫苗接种后的副作用轻微且可预测，没有住院病例;这一数据将有助于减少疫苗犹豫。
Vaccines are one of the best interventions developed for eradicating COVID-19. This study aimed to provide evidence on Sinopharm COVID-19 vaccine side effects. A cross-sectional survey study was conducted between January and April 2021 to collect data on the effects of the COVID-19 vaccine among individuals in the United Arab Emirates. Demographic data, vaccination and the response of people unwilling to take the COVID-19 vaccine were reported. Side effects post first vaccine dose of normal injection site pain, fatigue and headache were more common in participants aged ≤49 years versus >49 years, while pain at the vaccination site, fatigue, lethargy, headache and tenderness were the most common side effects post second dose in both groups. All side effects for both doses were more prevalent among participants aged ≤49 years. Side effects were more common in females compared with males for both doses. The most common reason for being unwilling to take the COVID-19 vaccine was that vaccines are not effective. Post-vaccination side effects for the first and second doses were mild and predictable, and there were no hospitalization cases; this data will help reduce vaccine hesitancy.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
7.8
作者：
Kounis NG;Koniari I;de Gregorio C;Velissaris D;Petalas K;Brinia A;Assimakopoulos SF;Gogos C;Kouni SN;Kounis GN;Calogiuri G;Hung MY
通讯作者：
Hung MY
影响因子：
6.4
作者：
Klein, Sabra L.;Pekosz, Andrew
通讯作者：
Pekosz, Andrew
DOI：
10.1016/s1473-3099(10)70049-9
发表时间：
2010-05
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Klein SL;Jedlicka A;Pekosz A
通讯作者：
Pekosz A
影响因子：
3.7
作者：
Haidere MF;Ratan ZA;Nowroz S;Zaman SB;Jung YJ;Hosseinzadeh H;Cho JY
通讯作者：
Cho JY